OncoMatch/Clinical Trials/NCT06483048
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Is NCT06483048 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Autologous MUC1-activated T-cells and Bendamustine for platinum-resistant fallopian tube carcinoma.
Treatment: Autologous MUC1-activated T-cells · Bendamustine · Cyclophosphamide — This phase I trial tests the safety, side effects, best dose of MUC1-activated T cells in treating patients with ovarian cancer that has come back after a period of improvement (relapsed) or that remains despite treatment (resistant). T cells are infection fighting blood cells that can kill tumor cells. The T cells given in this study will come from the patient and are made in a laboratory to recognize MUC1, a protein on the surface of tumor cells that plays a key role in tumor cell growth. These MUC1-activated T cells may help the body's immune system identify and kill MUC1 expressing ovarian tumor cells.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: MUC1 overexpression (IHC staining score > 0)
MUC1 expression in ovarian cancer tumor cells verified by immunohistochemistry (IHC) in a Clinical Laboratory Improvement Act (CLIA) laboratory. Heterogeneous tumor expression of MUC1 is acceptable. MUC1 expression by staining score greater than 0 is deemed positive for this study
Allowed: BRCA1 pathogenic mutation
Patients with BRCA1/2 mutations must have received prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor to be eligible
Allowed: BRCA2 pathogenic mutation
Patients with BRCA1/2 mutations must have received prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor to be eligible
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Relapsed or refractory ovarian cancer previously treated with or intolerant to at least one prior line of therapy with platinum chemotherapy
Cannot have received: MUC1-targeted therapy
Prior treatment targeting MUC1
Lab requirements
Blood counts
ANC ≥ 1500/mm^3; Lymphocyte count ≥ 1500/mm^3; Hemoglobin ≥ 8.0 g/dL; Platelet count ≥ 30,000/mm^3
Kidney function
Calculated creatinine clearance ≥ 30 ml/min using Cockcroft-Gault formula
Liver function
Total bilirubin ≤ 2.0 mg/dL unless Gilbert's syndrome (≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN); ALT and AST ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement)
ANC ≥ 1500/mm^3; Lymphocyte count ≥ 1500/mm^3; Hemoglobin ≥ 8.0 g/dL; Platelet count ≥ 30,000/mm^3; Total bilirubin ≤ 2.0 mg/dL unless patient has documented Gilbert's syndrome (≤ 3.0 x ULN and direct bilirubin ≤ 1.5 x ULN); ALT and AST ≤ 3 x ULN (≤ 5 x ULN for patients with liver involvement); Calculated creatinine clearance ≥ 30 ml/min using Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic in Arizona · Scottsdale, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify